Pharma 5.0

GE HealthCare drives growth with investment in AI-enabled medical devices

Published: 25-Jul-2025

GE HealthCare has topped a US Food and Drug Administration (FDA) list of AI-enabled medical device authorisations for the fourth year in a row with 100 listed authorisations to date in the US

This milestone reflects GE HealthCare’s continued research and development (R&D) investment and focus on developing AI solutions to advance precision care by enhancing medical devices throughout the care journey.

Smart devices, software and cloud-based solutions, which are central to GE HealthCare’s precision care strategy, help enhance outcomes for patients, improve the daily work of care teams, and boost healthcare professional efficiency.

These AI-enabled devices help solve customer challenges and are in high demand, which contributes to orders, revenue and growth for the company.

The momentum demonstrates GE HealthCare’s progress toward achieving its goal of securing more than 200 authorisations.

“Our sustained leadership in AI-enabled medical devices reflects our commitment to research and development, which is powering the creation of next-generation solutions."

"These solutions are designed to address the toughest challenges our customers are facing, including care team shortages and burnout, rising costs and inefficient workflows,” said Dr Taha Kass-Hout, GE HealthCare’s Global Chief Science and Technology Officer.

“As we continue to drive the industry forward, we remain committed to doing so in a responsible way, building in our Responsible AI principles at every stage of our product development, which include a focus on safety, validity, transparency, explainability and fairness.”

Examples of GE HealthCare’s AI solutions that are helping solve customer challenges and driving growth include

  • AI-based Auto Positioning uses deep learning to automatically detect anatomical landmarks, which are used to determine the patient’s orientation inside computed tomography (CT) and positron emission tomography (PET)/CT devices, including the Revolution Apex platform and Omni Legend. 
  • AIR Recon DL is a pioneering deep learning algorithm for image reconstruction that enables radiologists to achieve pin-sharp images quicker.
  • The LOGIQ Series ultrasound portfolio of systems empowers clinicians to scan, diagnose and treat a wide range of patients and conditions. 
  • Precision DL is deep learning-based image processing, available on the Omni Legend PET/CT system, that enhances image quality in PET/CT scans.
  • Venue Family point-of-care ultrasound systems with AI-powered Caption Guidance software provide real-time, step-by-step guidance to help even new ultrasound users capture cardiac views and diagnostic-quality images successfully.

"Reaching this milestone is also an important step along our journey of evolving from an imaging company to a healthcare solutions provider, enabling us to deliver holistic and integrated solutions that meet our customers’ needs today and will help enable them to stay ahead in a rapidly evolving healthcare environment,” said Kass-Hout.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
  2. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like